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To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women
with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367
incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all
neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95% CI
0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast,
corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not.
Further analyses by type of drug and dose revealed a dose–response gradient in the risk of cancer of the corpus uteri (P for linear
trend¼0.03), with women given X2250mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who
were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they
indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users.
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Several case reports in the 1980s, linking assisted conception and
ovarian cancer, raised concerns about the long-term health effects
of infertility treatment (Fishel and Jackson, 1989). These reports
prompted many investigations into potential associations between
exposure to fertility treatments used to stimulate ovulation and
cancer risks. Some earlier studies (Whittemore et al, 1992; Rossing
et al, 1994; Shushan et al, 1996) reported positive associations
between ovarian stimulation and risk of ovarian cancer, but others
did not confirm this. Raised risks have also been reported for
cancers of the breast (Burkman et al, 2003; Orge ´as et al, 2009),
endometrium (Ron et al, 1987; Modan et al, 1998; Althuis et al,
2005; Calderon-Margalit et al, 2008), thyroid (La Vecchia et al,
1999) and malignant melanoma of the skin (Rossing et al, 1995;
Calderon-Margalit et al, 2008), but again these findings were not
replicated in other studies.
A cause–effect relationship between infertility treatment and
cancer risks would have important implications for assisted
conception programmes, which have been expanding considerably
in recent years. A total of 34855 women had in vitro fertilisation
treatment in the United Kingdom in 2006 corresponding to 44275
cycles of treatment, a 6.8% increase in the number of patients
relative to the previous year (HFEA, 2008). We investigated the
long-term health effects of the use of ovarian-stimulation
treatments, with particular attention to potential cancer risks, in
a large British cohort of women investigated for ovulatory
disorders who have been followed-up for over 20 years.
MATERIALS AND METHODS
Study subjects were identified through two case series of women
who attended reproductive endocrinology practices in London.
The first consisted of 7425 women who attended the Royal Free
Hospital in 1963–1999 (Ginsburg and Hardiman, 1991). The
second was assembled at University College Hospital (Reproduc-
tive Medicine Unit) and comprised 1727 women (including five
also seen at the Royal Free Hospital), many of whom were treated
with clomiphene citrate in the 1960s and 1970s as part of the initial
evaluation of this drug, prior to it being available on the market.
The present follow-up study was approved by all the relevant
ethics committees.
From the meticulous clinical notes kept by the founders of these
case series, a trained abstractor extracted and computerised
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yrelevant data, including information on signs and symptoms at
presentation, final diagnosis, treatments prescribed (with number
of cycles and dose) and their outcome. Hospital records (mainly on
microfilms) and computer databases were also reviewed. Data on
underlying diagnoses and treatments were reviewed by a panel of
infertility clinicians and re-classified using more up-to-date and
standardised criteria. Underlying ovulatory disorders were classi-
fied according to the WHO classification (WHO, 1973). For the
specific purpose of this study, treatments were classified according
to their physiological effects on the ovary and endometrium into
five broader, and not-mutually exclusive, categories: (i) ovarian
stimulation; (ii) ovarian physiological stimulation; (iii) ovarian
suppression; (iv) endometrium stimulation; and (v) endometrium
suppression (as detailed in Table 1).
Study subjects were followed through the National Health
Service Central Register (NHSCR) in England and Wales to
ascertain their vital status, and to obtain information on site-
specific cancer incidence, cause-specific mortality and migrations.
A total of 7444 women out of the initial 9152 (81.3%) were traced
and flagged through this register. For 95% of the 1708 who could
not be traced, there was insufficient detailed information (e.g.,
name too common with no information on exact date of birth) or
the names were foreign suggesting that they might have been non-
UK residents. A further 89 subjects were excluded because flagging
was considered to be unreliable (n¼8), they were no longer NHS
patients at the time they joined the cohort (n¼79), or they have
subsequently undergone a sex change operation (n¼2). For a
further 183 women information on treatment was lacking and
these were excluded from any treatment-related analyses. Women
who were known to be still alive and resident in England and
Wales, and whose current general practitioner (GP) could be
traced through their Health Authorities, were sent (through their
GPs) a postal questionnaire to obtain further details on their
reproductive and lifestyle characteristics.
To compare mortality and cancer incidence with that in the
general population, expected numbers of deaths and cancers in the
cohort were calculated by applying England and Wales female
rates to the number of person-years at risk, stratifying by 5-year
calendar period and 5-year age bands. Time at risk for mortality
analyses was estimated from the date of first hospital visit (or the
date of first treatment for analysis by type of treatment) to death,
emigration, loss to follow-up, or 31 December 2005, whichever
occurred first. For cancer incidence analyses, time at risk was from
1 January 1971, when cancer registration reached national
coverage, or from date of hospital visit/treatment if these occurred
after that date, to the earliest of date of diagnosis of the first
primary malignancy, emigration, loss to follow-up, date of death,
or 31 December 2005. Period-age-standardised mortality (SMR)
and incidence ratios (SIRs) were then calculated as the ratio
between the observed and expected number of events (deaths or
cancers, respectively) in the cohort, with their 95% percent
confidence intervals (CI) estimated using an exact method
(Sasieni, 1995).
Data on mortality and cancer incidence for England and Wales
were provided by the Office for National Statistics as tabulations of
numbers of female cancers and deaths by single calendar year,
single year of age, and four-digit codes of the International
Classification of Diseases (ICD) (revision 7 (ICD-7) for 1961–1967;
ICD-8 for 1968–1978; ICD-9 for 1979–2000; and ICD-10 for 2001–
2005) (WHO, 1957, 1967, 1977, 1994). Appropriate bridging of ICD
codes across the various revisions was performed to ensure
comparability throughout the follow-up period.
To account for socioeconomic differences between the cohort
and the general population, we also obtained rates for England and
Wales by quintiles of socioeconomic deprivation as defined by the
Carstairs Index (Carstairs and Morris, 1989) and, from 1995
onwards, the income domain of the Index of Multiple Deprivation
(IMD) (DETR, 2000). Rates for the top two quintiles (the two most
affluent) of the national distribution of deprivation scores were
used to estimate expected number of events in the cohort as, at
that time, infertility treatment was sought mainly by women of
high socioeconomic status (68.6% of the women who completed
the questionnaire were in social classes I and II (the two most
affluent)) (OPCS, 1991), based on their own or their partner’s
occupation, with only 5.1% being in social classes IV and V (the
two least affluent); equivalent figures for England and Wales
females were 27.8 and 23.1%, respectively (OPCS/GRO, 1993).
Two approaches were used to compare study groups within the
cohort. In the first, the risk of dying from a particular cause, or of
developing a certain site-specific cancer, among patients ‘exposed’
to a given characteristic (e.g., treatment type) relative to the risk
among those ‘unexposed’ was estimated as the ratio between the
two corresponding SMRs, or SIRs, to take into account calendar
period and age effects. The 95% CI for these relative risks (RRs)
were calculated using an exact method (Breslow and Day, 1987).
The second approach used Cox proportional hazards models
(Clayton and Hills, 1993) to examine treatment effects in more
detail while adjusting for potential confounders. RRs were
estimated as hazard rate ratios in users relative to non-users of a
given treatment while adjusting for current age (as the analysis
time-scale); other variables were included in the regression models
to evaluate their roles as potential confounders or effect modifiers.
Because of the small number of cases assessment of confounding
was performed for each potential confounding variable one at a
time, by comparing the age-adjusted and the age-variable-adjusted
estimates within the subset of women with data on that variable.
The proportional hazard assumption, evaluated by visual exam-
ination and a formal test (Schoenfeld, 1982; Grambsch and
Therneau, 1994), was met for all models shown. All statistical
analyses were performed using Intercooled Stata 10.0 (Stata
Corporation, College Station, TX, USA).
RESULTS
The baseline characteristics of the women in the final study
population (n¼7355) were similar to those in the original cohort
(n¼9152) (Table 1). The mean age at presentation among the
participants was 28.1 years, with a mean follow-up of 21.4 years;
89% of the participants were followed-up for at least 10 years and
14% for at least 30 years. Half of the participants presented because
of menstrual disturbances (Table 1). After investigation, 24% were
diagnosed with a WHO type II ovulatory disorder, mainly with
polycystic ovarian syndrome. A total of 3196 (44.5%) patients
received ovarian-stimulation treatments, 1976 receiving clomi-
phene only, with a median number of cycles equal to two
corresponding to a median dose of 1000mg per woman; 18% were
prescribed more than the maximum of six cycles currently
recommended by the Committee on Safety of Medicines (1995).
A total of 1198 women were prescribed gonadotrophins (alone or
in combination with clomiphene), with a median number of cycles
per woman equal to three (Table 1).
Questionnaire data were available for 2545 participants (out of
the 4475 who were still alive and whose current GP could be traced
and was willing to forward the questionnaire to them; a response
rate of 56.9%). There was no evidence that respondents differed
from the remaining study population in terms of clinic attended
(79.8 vs 83.8%, respectively, attended the Royal Free Hospital), age
at initial clinical evaluation (mean±s.d.: 28.0±7.1 vs 28.5±8.4
years, respectively), or type of treatment (e.g., 29.6 vs 26.5% were
prescribed clomiphene only, respectively).
In all, 274 deaths occurred during follow-up to the end of 2005;
47% were from malignant neoplasms, including 39 from breast
cancer, 10 from ovarian cancer and 7 from cancer of corpus uteri
(hereafter referred to as cancer of the uterus) (Table 2). Relative to
the general population, mortality in the cohort was lower for all-
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ycauses (SMR¼0.89), reflecting lower risks for most specific causes
except, as expected, for endocrine and metabolic diseases
(SMR¼1.99) (Table 2). Analyses by cancer site showed increased
mortality in the whole cohort for cancers of the liver and biliary
tract (SMR¼2.68) and of the uterus (SMR¼3.02), with only the
latter being statistically significant (Table 2); in contrast, mortality
from cancers of the breast and ovary did not differ from those in
the general population. Further analyses stratified by type of
treatment revealed that the excess risk of dying from liver and
biliary cancer was confined to women who were prescribed
ovarian stimulation; these women had a four-fold increase
(RR¼4.19, based on small numbers; Table 2) in risk relative to
those not given this treatment. Similarly, women who were given
ovarian-stimulation drugs had more than two times (RR¼2.37)
the risk of dying from breast cancer than those who were not, with
this difference being statistically significant. In contrast, those
prescribed ovarian-stimulation drugs had only half the risk of
dying from cancers of the uterus (RR¼0.53) and ovary
Table 1 Baseline and follow-up characteristics of the study population
Original cohort (N¼9152) Study population (N¼7355)
Characteristic N
a Statistics N
a Statistics
Follow-up
Calendar year of initial clinical evaluation (n (%)) 9152 7355
1949–1969 781 (8.5) 366 (5.0)
1970–1979 2853 (31.2) 2200 (29.9)
1980–1989 3957 (43.2) 3454 (47.0)
1990–1999 1561 (17.1) 1335 (18.2)
Age at initial clinical evaluation (mean±s.d.) 8915 27.9±7.9 7355 28.1±7.9
Years of follow-up to end of 2005 (mean±s.d.) N/A N/A 7355 21.4±8.3
Years of follow-up for cancer incidence analyses (1971–
2005) (mean±s.d.)
N/A N/A 7317 20.7±8.0
Presentation symptoms
b (n (%)) 8666 7048
Infertility forX1 year 3234 (37.3) 2532 (35.9)
Hirsutism 2097 (24.2) 1801 (25.6)
Menstrual disturbances 4379 (50.5) 3560 (50.5)
Weight related 582 (6.7) 462 (6.6)
Other
b 853 (9.8) 727 (10.3)
Underlying diagnosis (n (%)) 7743 6361
WHO – group II
c 1803 (23.3) 1517 (23.9)
Not WHO group II-related diagnoses 5940 (76.7) 4844 (76.2)
Most common specific diagnoses:
d
Polycystic ovarian syndrome (PCOS) 1775 (22.9) 1494 (23.5)
Male factor 566 (7.3) 489 (7.7)
Thyroid disease 541 (7.0) 423 (6.7)
Anovulation, irregular ovulation, primary amenorrhoea
e 456 (5.9) 366 (5.8)
Weight-related ovulatory disorders 392 (5.1) 337 (5.3)
Hyperprolactinaemia 348 (4.5) 294 (4.6)
Treatment prescribed (n (%)) 8876 7172
Ovarian stimulation 3882 (43.7) 3196 (44.6)
Only clomiphene 2445 (63.0) 1976 (61.8)
Only gonadotrophins 243 ( 6.3) 190 (5.9)
Clomiphene+gonadotrophins 1168 (30.1) 1008 (31.5)
Physiological stimulation of ovary
f 662 (7.5) 562 (7.8)
Suppression of ovary
g 1150 (13.0) 984 (13.7)
Endometrium stimulation
h 5178 (58.3) 4163 (58.1)
Endometrium suppression
i 1364 (15.4) 1231 (17.2)
None of the above 2753 (31.0) 2176 (30.3)
Ovarian stimulation: total dose & no. of cycles (median (25th, 75th percentile))
j
Clomiphene – dose (mg/woman) 2662 1000 (350, 2100) 2241 1000 (350, 2250)
Clomiphene – no. of cycles/woman 3134 2 (1, 5) 2599 2 (1, 5)
Gonadotrophins – dose (number of ampoules/woman) 714 60 (27, 135) 643 60 (27, 138)
Gonadotrophins – no. of cycles/woman 717 3 (2, 6) 647 3 (2, 6)
aNumber of women with information on this variable.
bCategories are not mutually exclusive. The category ‘other’ comprises galactorrhoea (study population¼163), fertility
untested (n¼49), breast disease (n¼29), history of recurrent abortion/miscarriages (n¼1).
cIn addition to PCOS patients, this category comprised women with Cushing’s
syndrome or congenital adrenal hyperplasia.
dCategories are not mutually exclusive. Other diagnoses in the study population: tubal disease (n¼212), premature ovarian failure
(n¼134), history of past surgical intervention (n¼103), endometriosis (n¼75), cervical factor (n¼70), pituitary tumour (n¼48), congenital adrenal hyperplasia (n ¼30),
hypogonadotrophic hypogonadism (n¼29), gonadal dysgenesis (n¼26), Cushing’s syndrome (n¼14), uterine factor (n¼13), history of past benign ovarian tumour (n¼12),
secondary hypopituitarism (following neurosurgery or radiation: n¼4), history of recurrent abortion/miscarriage (n¼3), Turner’s syndrome (n¼2l).
eAn additional 105 women
in the original cohort and 89 in the study population were registered as being menopausal.
fIncludes gonadotrophin-releasing hormones; bromocriptin and dopamine agonists.
gIncludes inhibitors of gonadotrophins; combined oral contraceptives, male sex hormones and cyproterone acetate.
hIncludes ovarian stimulation treatments, gonadotrophin-
releasing hormones, bromocriptine, dopamine agonists, oestrogens and tamoxifen
iIncludes inhibitors of gonadotrophins, progesterone, male sex hormones, androgen agonists
(danazol, gestrinone) and cyproterone acetate
jAmong users of any given drug only.
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y(RR¼0.57) of those not given such drugs (Table 2), but these
estimates were rather imprecise.
A total of 367 incident malignant neoplasms occurred from
1971–2005, comprising 177 breast, 31 uterine and 21 ovarian
cancers. Relative to the general population, cohort members had
increased risks of developing cancers of the breast (SIR¼1.13),
uterus (SIR¼2.02) and nervous system (SIR¼1.91), albeit only
significant for the latter two, but a significantly lower risk of
developing cervical cancer (SIR¼0.21) (Table 3). Analyses
stratified by type of treatment showed that, relative to the general
population, women who were prescribed ovarian stimulation had a
borderline raised risk of developing a malignant neoplasm
(SIR¼1.10), with significant increased risks for cancers of the
breast (SIR¼1.26) and uterus (SIR¼2.31). There were also non-
Table 2 Mortality in the cohort for selected disease categories, by type of treatment
All women (n¼7355)
Women prescribed ovarian-
stimulating drugs (n¼3194)
a
Women not prescribed
ovarian-stimulating drugs
(n¼3976)
a
Cause of death ICD-10 O/E
b SMR (95% CI) O/E
b SMR (95% CI) O/E
b SMR (95% CI) RR (95% CI)
c
All causes A00-Z99 274/306.5 0.89 (0.79–1.01) 132/141.9 0.93 (0.78–1.10) 134/157.7 0.85 (0.71–1.01) 1.09 (0.85–1.40)
All malignant neoplasms C00-C85, C88-C94.3,
C94.7-C97.9, D32,
D33, D42, D43
126/143.3 0.88 (0.73–1.05) 69/70.0 0.99 (0.77–1.25) 54/70.1 0.77 (0.58–1.01) 1.28 (0.88–1.86)
Digestive system C15-C26, C48 20/24.5 0.82 (0.50–1.26) 8/11.5 0.69 (0.30–1.37) 12/12.5 0.96 (0.50–1.68) 0.72 (0.26–1.92)
Colon and rectum C18-C21 8/10.5 0.76 (0.33–1.50) 3/5.0 0.60 (0.12–1.76) 5/5.3 0.94 (0.30–2.19) 0.64 (0.10–3.31)
Liver and biliary tract C22-C24 5/1.9 2.68 (0.87–6.25) 4/0.9 4.48 (1.22–11.47) 1/0.9 1.07 (0.03–5.95) 4.19 (0.41–206.48)
Respiratory system C30-C39, C45 16/21.0 0.76 (0.44–1.24) 7/10.0 0.70 (0.28–1.44) 9/10.6 0.85 (0.39–1.61) 0.82 (0.26–2.48)
Malignant melanoma C43 2/2.7 0.73 (0.09–2.63) 1/1.4 0.72 (0.02–4.03) 1/1.3 0.78 (0.02–4.32) 0.93 (0.01–73.11)
Breast C50 39/40.3 0.97 (0.69–1.32) 28/20.4 1.37 (0.91–1.98) 11/19.0 0.58 (0.29–1.04) 2.37 (1.14–5.27)
Corpus uteri C54, C55 7/2.3 3.02 (1.21–6.23) 2/1.1 1.81 (0.22–6.53) 4/1.2 3.42 (0.93–8.76) 0.53 (0.05–3.69)
Ovary C56, C57.0-C57.4 10/11.6 0.86 (0.41–1.58) 3/5.8 0.52 (0.11–1.51) 5/5.6 0.90 (0.29–2.10) 0.57 (0.09–2.95)
Circulatory system I00-I99 46/68.5 0.67 (0.49–0.90) 20/28.8 0.69 (0.42–1.07) 26/38.4 0.68 (0.44–0.99) 1.03 (0.54–1.91)
Respiratory system J00-J99 17/22.0 0.77 (0.45–1.24) 11/9.3 1.19 (0.59–2.12) 5/12.3 0.41 (0.13–0.95) 2.92 (0.93–10.71)
Digestive system K00-K93 15/17.2 0.87 (0.49–1.44) 4/8.2 0.49 (0.13–1.25) 10/8.6 1.16 (0.56–2.14) 0.42 (0.10–1.45)
Endocrine and metabolic E00-E90 10/5.0 1.99 (0.95–3.66) 5/2.3 2.22 (0.72–5.18) 5/2.7 1.88 (0.61–4.39) 1.18 (0.27–5.13)
Nervous system, eye and ear G00-G99
H00-H95 9/9.7 0.92 (0.42–1.75) 5/4.6 1.09 (0.35–2.54) 4/4.9 0.82 (0.22–2.09) 1.33 (0.29–6.70)
CI¼confidence interval; SMR¼standardised mortality ratio.
aInformation on treatment missing for 183 women. Two additional women who were known to have been treated
with ovarian-stimulating drugs were excluded from the analyses on treatment, because information on the start date of treatment was unavailable. Among these women eight
deaths occurred during the follow-up.
bNumber of observed (O) and expected (E) deaths estimated assuming the cohort experienced the same calendar year and age-specific
mortality rates as the England and Wales female general population.
cRelative risk (95% confidence interval) associated with ovarian stimulation as estimated by the ratio between
the two corresponding SMRs.
Table 3 Cancer incidence in the cohort for selected sites, by type of treatment
All women (n¼7317)
a
Women prescribed ovarian-
stimulating drugs (n¼3180)
a
Women not prescribed
ovarian-stimulating drugs
(n¼3949)
a
Cancer ICD-10 O/E
b SIR (95% CI) O/E
b SIR (95% CI) O/E
b SIR (95% CI) RR (95% CI)
c
All C00-C85, C88-C94.3,
C94.7-C97.9, D32,
D33, D42, D43
367/358.8 1.02 (0.92–1.13) 197/179.1 1.10 (0.95–1.26) 161/170.8 0.94 (0.80–1.10) 1.17 (0.94–1.45)
Digestive system C15-C26, C48 29/41.2 0.70 (0.47–1.01) 15/19.8 0.76 (0.42–1.25) 14/20.6 0.68 (0.37–1.14) 1.11 (0.50–2.49)
Colorectum C18-C21 17/25.1 0.68 (0.39–1.08) 11/12.2 0.90 (0.45–1.62) 6/12.4 0.48 (0.18–1.05) 1.87 (0.64–6.17)
Liver and biliary tract C22-C24 3/2.4 1.25 (0.26–3.65) 3/1.2 2.59 (0.53–7.58) 0/1.2 0.00 (0.00–3.09) 5.05 (0.29–6254)
Respiratory system C30-C39, C45 16/25.5 0.63 (0.36–1.02) 7/12.3 0.57 (0.23–1.17) 9/12.7 0.71 (0.32–1.35) 0.80 (0.25–2.42)
Bone and articular cartilage C40, C41 4/2.8 1.42 (0.39–3.63) 1/1.4 0.74 (0.02–4.10) 3/1.4 2.17 (0.45–6.36) 0.34 (0.01–4.21)
Malignant melanoma of skin C43 14/16.7 0.84 (0.46–1.41) 6/8.1 0.74 (0.27–1.60) 8/8.1 0.99 (0.43–1.95) 0.74 (0.21–2.44)
Breast C50 177/157.3 1.13 (0.97–1.30) 102/80.7 1.26 (1.03–1.53) 72/72.6 0.99 (0.78–1.25) 1.27 (0.93–1.75)
Cervix uteri C53 5/23.5 0.21 (0.07–0.50) 1/11.6 0.09 (0.00–0.48) 4/11.1 0.36 (0.10–0.92) 0.24 (0.00–2.43)
Corpus uteri C54, C55 31/15.3 2.02 (1.37–2.87) 18/7.8 2.31 (1.37–3.64) 12/7.2 1.66 (0.86–2.90) 1.39 (0.63–3.16)
Ovary C56, C57.0-C57.4 21/21.7 0.97 (0.60–1.48) 12/10.9 1.10 (0.57–1.93) 8/10.3 0.78 (0.34–1.53) 1.42 (0.53–3.99)
Urinary tract C64-C68 5/9.3 0.54 (0.17–1.25) 1/4.5 0.22 (0.01–1.24) 3/4.6 0.65 (0.13–1.90) 0.34 (0.01–4.27)
Nervous system (incl. benign
and unspecified), eye and ear
C69-C72, D32, D33,
D42, D43
14/7.3 1.91 (1.05–3.21) 7/3.6 1.96 (0.79–4.03) 5/3.5 1.42 (0.46–3.30) 1.38 (0.38–5.52)
Thyroid and other glands C73-C75 6/5.1 1.18 (0.43–2.57) 4/2.4 1.66 (0.45–4.25) 2/2.5 0.79 (0.10–2.86) 2.10 (0.30–23.2)
Lymphatic and haematopoietic
system
C81-C85, C88, C90.0-
C90.2, C91.0-C91.4,
C91.5-C94.3, C94.6-
C94.9, C96.0-C96.3,
C96.7, C96.9
32/22.9 1.40 (0.95–1.97) 14/11.1 1.26 (0.69–2.12) 17/11.2 1.51 (0.88–2.42) 0.83 (0.38–1.80)
CI¼confidence interval; SIR¼standardised incidence ratio.
aNumbers differ slightly from those shown in Table 2 because of deaths, cancer incidence and migrations prior to 1
January 1971 when national follow-up for cancer incidence began. Information on treatment was missing for 182 women eligible for analyses on incidence, and information on the
start date of treatment was missing for an additional six women: these women were excluded from the analyses on treatment.
bNumbers of observed (O) and expected (E)
incident cancers estimated assuming the cohort experienced the same age and calendar year-specific cancer incidence rates as the England and Wales female general population.
cRelative risk (95% confidence interval) associated with ovarian stimulation as estimated by the ratio between the two corresponding SIRs.
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(SIR¼2.59) and for nervous (SIR¼1.96) and lymphatic and
haematopoietic systems (SIR¼1.66), as well as a significantly
lower risk for cervical cancer (SIR¼0.09). Women who were not
prescribed ovarian stimulation had no increase in the risk of breast
cancer (SIR¼0.99), but a non-significant increased risk of cancer
of the uterus (SIR¼1.66); they also had a significantly lower risk
of cervical cancer (SIR¼0.36). Thus, risks among women who
were prescribed ovarian stimulation relative to those not
prescribed such treatments were not significantly raised for any
cancer site although there were borderline increases for all
neoplasms (RR¼1.17) and cancer of the breast (RR¼1.27)
(Table 3). There were no associations between any of the other
type of treatment categories (Table 1) and risks of cancers of the
breast, uterus or ovary (data not shown).
The lower mortality in the cohort relative to the general
population was mainly accounted by socioeconomic differences
between the two populations as most SMRs became closer to unity
when England and Wales rates for the two most affluent quintiles
of the national distribution of area-based deprivation scores were
used to derive expected numbers (e.g., the SMRs for deaths from
circulatory, respiratory and digestive systems increased from 0.67,
0.77 and 0.87 (Table 2) to 0.96, 1.13 and 1.34, respectively);
similarly, the magnitude of most SIRs increased slightly. However,
the magnitude of the RRs associated with ovarian stimulation were
little affected, with those for cancers of the breast, uterus and ovary
being 1.27 (95% CI 0.93, 1.74), 1.40 (0.64, 3.18) and 1.40 (0.53,
3.96), very similar to those presented in Table 3.
Within cohort analyses do not suggest that associations between
ovarian stimulation and risks for cancers of the breast and uterus
were confounded by other risk factors for these cancers (small
numbers precluded similar analyses for ovarian cancer). Having
ever been pregnant as recorded in the clinical notes was not a
confounder of the association of ovarian stimulation with cancers
of the breast (age-adjusted RR¼1.30 (95% CI 0.96, 1.77); age and
ever-pregnancy-adjusted¼RR 1.28 (0.94, 1.74)) or uterus (age-
adjusted RR¼1.53 (0.72, 3.23); age- and ever-pregnancy-adjusted
RR¼1.73 (0.81, 3.67)). Similarly, adjustment for having ever been
pregnant before treatment, or for having become pregnant as a
result of it, did not affect the magnitude of these cancer
associations. In the subset of women who completed the
questionnaire (comprising 41 treated and 28 untreated breast
cancer cases and a total of 30583 person-years of follow-up) the
age-adjusted RR associated with ovarian stimulation was 1.02 (95%
CI 0.63, 1.65) and its magnitude changed little with further
adjustment for having ever been pregnant (1.02 (0.63, 1.66)), age at
first pregnancy (1.03 (0.61, 1.75)), ever-use of oral contraceptives
(1.01 (0.62, 1.64)) or hormone replacement therapy (1.05 (0.65,
1.71)), or a positive family history of breast cancer (1.05 (0.65,
1.72)). The small number of cases among respondents precluded
similar analyses for cancer of the uterus.
Ovarian-stimulation treatment was associated with underlying
diagnosis with, for instance, higher proportions of treated vs
untreated women among WHO type II ovulatory disorders (53 vs
47%), but lower proportions among thyroid disorders (39 vs 61%)
and weight-related problems (48 vs 52%). There were, however, no
associations between underlying diagnosis and cancer risks except
that women with type II ovulatory disorders had an elevated risk of
cancer of the uterus (2.82 (1.13, 6.70)) relative to women with other
diagnoses. Further adjustment for underlying diagnosis did not
affect the magnitude of the ovarian stimulation – cancer of the
uterus association (e.g., age-adjusted and age and WHO type II-
adjusted RR: 1.53 (0.72, 3.23) and 1.48 (0.60, 3.63), respectively).
There was also no evidence that the ovarian-stimulation effects
were modified by any of these risk factors although the power of
the study to detect interactions was limited. In particular, the
magnitude of the associations with cancer risks was not modified
by age when the treatment was first prescribed. Only 121 women
developed ovarian hyperstimulation syndrome and the small
numbers of cases among them (only one cancer of the breast
and one of the uterus) precluded examination of whether risks
were particularly elevated in this subgroup.
More detailed analyses by type of ovarian stimulation drug
prescribed showed that the risk of developing breast cancer was
significantly elevated among women who were prescribed clomi-
phene only (SIR¼1.41), but this risk was not higher than that
among women who were not treated (ovarian stimulation or any
other) (Table 4). There were no clear dose–response trends in the
risk of breast cancer with time since first treatment, total
cumulative dose, or number of cycles of clomiphene, although
women in the highest exposure categories had the highest risks
(Table 4). The risks of cancer of the uterus were significantly raised
among women who took ovarian-stimulation drugs but again none
of the risks were significantly higher than those observed among
the women not given any type of treatment. There were no clear
trends in the risk of this cancer with time since first treatment, but
there was a positive trend with total cumulative dose and number
of cycles of clomiphene, with the first being significant (P for linear
trend¼0.034). Thus, women who took X2250mg were 2.62 (95%
CI 0.94, 6.82) times more likely to develop cancer of the uterus
than those who were not treated. The risk of cancer of the ovary
was not associated with any of the ovarian-stimulation treatments,
and there was no evidence of any trends in risk with time since
first use, total cumulative dose or number of cycles of clomiphene,
but estimates were based on small numbers. Risks for any of these
three cancer sites were not associated with time since first
treatment with gonadotrophins or number of cycles or ampoules,
but again relevant numbers were small (not shown).
DISCUSSION
This cohort study has several strengths. Notably, in the absence of
trials, cohort studies are the next best design because information
on exposures is obtained prior to onset of disease. Linkage to the
NHSCR ensured that information on cause-specific mortality and
cancer incidence was also unbiased relative to the exposure status
of the cohort members and minimised losses to follow-up. Second,
the study had a long follow-up, allowing examination of long-term
effects of ovarian stimulation. Third, it benefited from detailed
information on causes of infertility and drug exposures from
medical records as well as on cancer risk predictors obtained
through completed questionnaires (although the latter only for a
subset). Fourth, about one fifth of women were exposed to high
levels of ovarian-stimulation drugs, well above currently recom-
mended maximum levels. Fifthly, the availability of an internal
comparison group may have minimised possible confounding by
any factors correlated with treatment-seeking behaviour, because
women who attended the two reproductive endocrinology
practices are likely to differ from the general population in several
respects. In particular, our study confirmed that women who seek
infertility treatments tend to be healthier and of a higher
socioeconomic background as those in the general population.
Finally, the availability of information on underlying diagnosis and
other risk factors also enabled adjustment for a variety of potential
confounding factors.
Weaknesses of our study include the fact that follow-up was
possible only for 80% of the original cohort; however, there was no
evidence that those untraced through the NHSCR differed from
those who were traced. Although the number of cancer cases
accrued during the follow-up was larger than in most similar
cohorts (Venn et al, 1995, 1999; Doyle et al, 2002; Klip et al, 2002),
although not all (Brinton et al, 2004; Jensen et al, 2007; Calderon-
Margalit et al, 2008: Jensen et al, 2009), the numbers for certain
sites, particularly uterus and ovary, were too small to provide
reliable estimates. The numbers will increase with increasing
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risk sites are high. Follow-up for cancer incidence was possible
only from 1971, but although we may have missed some earlier
cases, most women were recruited later. Data on various potential
confounding variables were available but its quality and complete-
ness were not always ideal, being limited to women who were still
alive and traceable at the time of the re-contact, hence residual
confounding by these and other correlates of infertility cannot be
excluded.
Our study found increased incidence of, and mortality from,
breast cancer among women who were prescribed ovarian-
stimulation treatments relative to those who were not, albeit the
relative risk was significant only for mortality data. Further
analyses by cumulative dose, and number of cycles did not reveal
any clear dose–response gradients. The lack of such trends would
argue against a true cause–effect relationship. This interpretation
would be consistent with findings from most cohort (Modan et al,
1998; Venn et al, 1999; Klip et al, 2002; Doyle et al, 2002; Brinton
et al, 2004) and case–control studies (Weiss et al, 1998; Ricci et al,
1999) that have assessed the relationship between fertility
treatments and breast cancer risk, which have not found any
overall associations, although some (Jensen et al, 2007; Orge ´as
et al, 2009) reported increases in specific subgroups.
This study provides no evidence that ovarian stimulation is
associated with an elevated risk of ovarian cancer. In contrast,
some earlier case series and epidemiological studies (Whittemore
et al, 1992; Rossing et al, 1994; Shushan et al, 1996) reported
positive associations, with risk being particularly high in the
subgroup of nulligravid women, whereas among those who
took drugs but did achieve a pregnancy the risk was not
significantly different from that among gravid women without
a history of infertility. More recent cohort (Modan et al, 1998;
Venn et al, 1999; Klip et al, 2002; Doyle et al, 2002; Brinton et al,
2004; Calderon-Margalit et al, 2008; Jensen et al, 2009) and
case–control (Ness et al, 2003) studies, however, have failed to
find any such association. The lack of clear trends with time since
start of treatment would also argue against the hypothesis that
ovulation stimulation induces growth of pre-existing latent
tumours.
There was some evidence that cancer of the uterus may be
associated with ovarian stimulation, with risks increasing with
increasing cumulative dose of clomiphene and, possibly, number
of cycles. Few studies have examined this question but three large
cohort studies reported increases among women exposed to high
doses or with longer follow-up (Modan et al, 1998; Althuis et al,
2005; Calderon-Margalit et al, 2008). Such a link would be
biologically credible as clomiphene and tamoxifen are both
selective estrogen-receptor modulators and tamoxifen use has
been shown to be associated with an increased risk of cancer of the
uterus (Swerdlow et al, 2005). Although high doses of clomiphene
may have been preferentially given to women with polycystic
ovarian syndrome, a known risk factor for cancer of the uterus,
adjustment for underlying diagnosis only slightly reduced the
magnitude of the risk estimate.
Table 4 Risks of cancers of the breast, corpus uteri, and ovary by type of ovarian-stimulation treatment, time since first treatment, and dose
Cancer of breast (n¼174) Cancer of corpus uteri (n¼30) Cancer of ovary (n¼20)
O/E
a SIR (95% CI) RR
b (95% CI) O/E
a SIR (95% CI) RR
b (95% CI) O/E
a SIR (95% CI) RR
b (95% CI)
Type of treatment
c
No treatment 45/41.1 1.10 (0.80–1.47) 1 (baseline) 6/4.0 1.50 (0.55–3.27) 1 (baseline) 3/5.7 0.52 (0.11–1.53) 1 (baseline)
Ovarian stimulation 102/80.7 1.26 (1.03–1.53) 1.15 (0.80–1.68) 18/7.8 2.31 (1.37–3.64) 1.53 (0.58–4.72) 12/10.9 1.10 (0.57–1.93) 2.10 (0.57–11.60)
Clomiphene only 66/46.8 1.41 (1.09–1.79) 1.29 (0.87–1.92) 10/4.5 2.23 (1.07–4.11) 1.49 (0.49–4.98) 7/6.3 1.11 (0.44–2.28) 2.11 (0.48–12.63)
Gonadotrophins only 5/5.3 0.94 (0.31–2.20) 0.86 (0.27–2.16) 1/0.5 1.93 (0.05–10.75) 1.28 (0.03–10.59) 0/0.7 0.00 (0.00–5.19) 1.34 (0.00–26.52)
Both 31/28.4 1.09 (0.74–1.55) 1.00 (0.61–1.61) 7/2.8 2.51 (1.01–5.16) 1.67 (0.48–6.01) 5/3.8 1.31 (0.43–3.06) 2.50 (0.49–16.09)
Time since first treatment (years)
Super-ovulation
None 72/72.6 0.99 (0.78–1.25) 1 (baseline) 12/7.2 1.66 (0.86–2.90) 1 (baseline) 2/1.8 1.10 (0.13–3.96) 1 (baseline)
o10 9/12.9 0.70 (0.32–1.32) 0.70 (0.31–1.41) 2/0.7 2.80 (0.34–10.12) 1.69 (0.18–7.58) 5/4.0 1.24 (0.40–2.89) 1.41 (0.15–7.05)
10–19 44/31.6 1.39 (1.01–1.87) 1.40 (0.94–2.07) 7/2.5 2.85 (1.15–5.88) 1.72 (0.57–4.73) 5/5.0 1.00 (0.32–2.33) 1.59 (0.41–5.51)
X20 49/36.2 1.35 (1.00–1.79) 1.36 (0.93–1.99) 9/4.6 1.94 (0.89–3.68) 1.17 (0.43–3.02) 2/1.8 1.10 (0.13–3.96) 1.28 (0.33–4.44)
P for linear trend
d 0.15 0.46 0.84
Clomiphene only
None 77/78.2 0.98 (0.78–1.23) 1 (baseline) 13/7.8 1.67 (0.89–2.86) 1 (baseline) 8/11.0 0.73 (0.31–1.43) 1 (baseline)
o10 6/7.0 0.85 (0.31–1.86) 0.87 (0.31–1.98) 0/0.4 0.00 (0.00–9.33) 0.76 (0.00–8.32) 1/1.0 0.97 (0.02–5.40) 1.33 (0.03–9.96)
10–19 25/18.2 1.38 (0.89–2.03) 1.40 (0.85–2.22) 6/1.4 4.34 (1.59–9.44) 2.59 (0.81–7.31) 3/2.3 1.28 (0.26–3.74) 1.77 (0.30–7.36)
X20 35/21.6 1.62 (1.13–2.25) 1.65 (1.07–2.48) 4/2.7 1.48 (0.40–3.80) 0.89 (0.21–2.87) 3/3.0 1.01 (0.21–2.97) 1.40 (0.24–5.83)
P for linear trend
d 0.15 0.58 0.95
Total cumulative dose (mg)
Clomiphene (all)
None 77/78.2 0.98 (0.78–1.23) 1 (baseline) 13/7.8 1.67 (0.89–2.86) 1 (baseline) 4/3.0 1.34 (0.36–3.42) 1 (baseline)
o900 28/22.4 1.25 (0.83–1.81) 1.27 (0.79–1.98) 2/2.0 0.98 (0.12–3.53) 0.58 (0.06–2.58) 4/2.4 1.65 (0.45–4.23) 1.84 (0.41–6.88)
900–2249 19/17.4 1.09 (0.66–1.71) 1.11 (0.63–1.85) 4/1.8 2.22 (0.61–5.70) 1.33 (0.32–4.30) 1/2.4 0.41 (0.01–2.29) 2.28 (0.50–8.50)
X2250 27/17.8 1.52 (1.00–2.20) 1.54 (0.95–2.41) 8/1.8 4.39 (1.89–8.64) 2.62 (0.94–6.82) 8/11.0 0.73 (0.31–1.43) 0.57 (0.01–4.23)
P for linear trend
d 0.50 0.034 0.34
Number of cycles
Clomiphene (all)
None 77/78.2 0.98 (0.78–1.23) 1 (baseline) 13/7.8 1.67 (0.89–2.86) 1 (baseline) 8/11.0 0.73 (0.31–1.43) 1 (baseline)
1–3 24/18.6 1.29 (0.83–1.92) 1.31 (0.79–2.10) 2/1.7 1.18 (0.14–4.28) 0.71 (0.08–3.13) 3/2.5 1.20 (0.25–3.52) 1.66 (0.28–6.91)
4–9 13/10.8 1.21 (0.64–2.06) 1.23 (0.62–2.22) 3/1.1 2.64 (0.55–7.73) 1.58 (0.29–5.75) 2/1.5 1.32 (0.16–4.76) 1.82 (0.19–9.11)
X10 9/5.0 1.80 (0.82–3.42) 1.83 (0.81–3.66) 2/0.5 3.71 (0.45–13.41) 2.22 (0.24–9.80) 0/0.7 0.00 (0.00–5.25) 0.98 (0.00–12.01)
P for linear trend
d 0.52 0.22 0.50
CI¼confidence interval; SIR¼standardised incidence ratio.
aNumbers of observed (O) and expected (E) incident cancers estimated assuming the cohort experienced the same
calendar year and age-specific incidence rates as the England and Wales female general population.
bRelative risk (95% confidence interval) as estimated by the SIR ratio.
cTreatments are not mutually exclusive.
dEstimated only among those women who were prescribed the treatment.
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malignant melanoma of the skin, or thyroid cancer. There was
some evidence suggestive of a positive association with cancer of
the liver and biliary tract, but this may be a chance finding (based
on only three cases). Such a link has not been reported earlier but
it has some biological plausibility as oral contraceptive use is
known to be associated with increased risks of benign hepatic
adenoma (Edmondson et al, 1976) and liver cancer (IARC, 1999).
The significantly lower risk of cervical cancer in this cohort
relative to the general population is consistent with a possible
surveillance bias and the fact that parity increases the risk of this
cancer (ICESCC, 2006). There is some evidence in our study that
risk may be somewhat lower among women who were exposed to
ovarian stimulation than among those who were not (RR¼0.24;
Table 3), but the small number of cases precluded proper
examination of dose–response effects.
Overall, the results of this study do not support strong
associations between ovulation-stimulation treatments and cancer
risks, with the exception of possible increases in the risk of cancers
of the uterus and of the liver and biliary tract. These findings
support the need for continuing monitoring of the long-term
effects of these treatments.
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